Key facts
- This page summarizes Harry Sloan's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2024, 16:35.
Harry Sloan - 12 Jun 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)
- Reporting relationship
- Director
- Issuer ticker
- DNA
- Reported as of
- 12 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 16:35:56 UTC
- Prior SEC filing
- 14 May 2024
- Next SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen Tepichin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Harry Sloan filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 14 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNA
transaction
Class A Common Stock
Options Exercise
- Transaction value
- Shares
- +105,263
- Change %
- +15%
- Price
- Shares after
- 823,803
- Date
- 12 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -105,263
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Jun 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 105,263
- Exercise price
- $0.000000
- Footnotes
- F1, F2
DNA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +432,900
- Change %
- Price
- $0.000000
- Shares after
- 432,900
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 432,900
- Exercise price
- $0.000000
- Footnotes
- F1, F3
DNA
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +571,428
- Change %
- Price
- $0.000000
- Shares after
- 571,428
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 571,428
- Exercise price
- $0.4620
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Footnote F2
In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Footnote F3
The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
Footnote F4
In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.